Literature DB >> 31240375

[Screening for prostate cancer using prostate-specific antigen (PSA) : A commentary on a systematic review and meta-analysis].

A Borkowetz1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31240375     DOI： 10.1007/s00120-019-0990-6

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  23 in total

1.  Long-Term Outcome of a Single Intervention Population Based Prostate Cancer Screening Study.

Authors:  Per-Olof Lundgren; Anders Kjellman; Ulf Norming; Ove Gustafsson
Journal:  J Urol       Date:  2018-02-01       Impact factor: 7.450

2.  Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.

Authors:  Richard M Martin; Jenny L Donovan; Emma L Turner; Chris Metcalfe; Grace J Young; Eleanor I Walsh; J Athene Lane; Sian Noble; Steven E Oliver; Simon Evans; Jonathan A C Sterne; Peter Holding; Yoav Ben-Shlomo; Peter Brindle; Naomi J Williams; Elizabeth M Hill; Siaw Yein Ng; Jessica Toole; Marta K Tazewell; Laura J Hughes; Charlotte F Davies; Joanna C Thorn; Elizabeth Down; George Davey Smith; David E Neal; Freddie C Hamdy
Journal:  JAMA       Date:  2018-03-06       Impact factor: 56.272

3.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Claudine Isaacs; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Ann W Hsing; Grant Izmirlian; Paul F Pinsky; Barnett S Kramer; Anthony B Miller; John K Gohagan; Philip C Prorok
Journal:  J Natl Cancer Inst       Date:  2012-01-06       Impact factor: 13.506

4.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.

Authors:  Laurence Klotz; Danny Vesprini; Perakaa Sethukavalan; Vibhuti Jethava; Liying Zhang; Suneil Jain; Toshihiro Yamamoto; Alexandre Mamedov; Andrew Loblaw
Journal:  J Clin Oncol       Date:  2014-12-15       Impact factor: 44.544

5.  Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.

Authors:  J L Donovan; F C Hamdy; J A Lane; D E Neal; M Mason; C Metcalfe; E Walsh; J M Blazeby; T J Peters; P Holding; S Bonnington; T Lennon; L Bradshaw; D Cooper; P Herbert; J Howson; A Jones; N Lyons; E Salter; P Thompson; S Tidball; J Blaikie; C Gray; P Bollina; J Catto; A Doble; A Doherty; D Gillatt; R Kockelbergh; H Kynaston; A Paul; P Powell; S Prescott; D J Rosario; E Rowe; M Davis; E L Turner; R M Martin
Journal:  N Engl J Med       Date:  2016-09-14       Impact factor: 91.245

6.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.

Authors:  Nicolas Mottet; Joaquim Bellmunt; Michel Bolla; Erik Briers; Marcus G Cumberbatch; Maria De Santis; Nicola Fossati; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Vsevolod B Matveev; Paul C Moldovan; Roderick C N van den Bergh; Thomas Van den Broeck; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Ivo G Schoots; Thomas Wiegel; Philip Cornford
Journal:  Eur Urol       Date:  2016-08-25       Impact factor: 20.096

7.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Liisa Määttänen; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Chris H Bangma; Sigrid Carlsson; Donella Puliti; Arnauld Villers; Xavier Rebillard; Matti Hakama; Ulf-Hakan Stenman; Paula Kujala; Kimmo Taari; Gunnar Aus; Andreas Huber; Theo H van der Kwast; Ron H N van Schaik; Harry J de Koning; Sue M Moss; Anssi Auvinen
Journal:  Lancet       Date:  2014-08-06       Impact factor: 79.321

8.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

9.  Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline.

Authors:  Kari A O Tikkinen; Philipp Dahm; Lyubov Lytvyn; Anja F Heen; Robin W M Vernooij; Reed A C Siemieniuk; Russell Wheeler; Bill Vaughan; Awah Cletus Fobuzi; Marco H Blanker; Noelle Junod; Johanna Sommer; Jérôme Stirnemann; Manabu Yoshimura; Reto Auer; Helen MacDonald; Gordon Guyatt; Per Olav Vandvik; Thomas Agoritsas
Journal:  BMJ       Date:  2018-09-05

10.  Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis.

Authors:  Dragan Ilic; Mia Djulbegovic; Jae Hung Jung; Eu Chang Hwang; Qi Zhou; Anne Cleves; Thomas Agoritsas; Philipp Dahm
Journal:  BMJ       Date:  2018-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.